ORMP — ORAMED PHARMACEUTICALS INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1176309 ·
Last close
$3.87
Market Cap
$168.29M
52W High
$5.47
52W Low
$2.16
ADV30
132,348
Next earnings
2026-11-12
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 0 -4,104,000 18,410,000 400,920,000 28,934,000 61,832,000
Jun 2026 0 0 -2,766,000 78,156,000 369,643,000 15,245,000 52,170,000
Mar 2026 0 0 -3,659,000 38,310,000 268,847,000 13,202,000 30,571,000
Dec 2025 0 0 -5,672,000 10,009,000 230,864,000 45,947,000 31,120,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,206,000
Investing CF
$21,502,000
Financing CF
$-16,683,000
CapEx
$-2,139,000
Dividends Paid
$-10,442,000
Buybacks
$-4,370,000
EPS Diluted TTM
$4.19
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-6,965,000
Inventory
—
Receivables
$622,000
ST Investments
$35,367,000
EBIT TTM
$62,823,000
Pretax Income TTM
$220,275,000
Interest Exp TTM
$2,558,000
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-16,080,000
Free Cash Flow
$-379,625
Enterprise Value
$109,094,848
Total Cash
$53,768,000
Total Debt
$1,530,000
Shares Out
43,485,942
Trailing EPS
$4.13
Book Value
$7.84
ROE
53.5%
ROA
-3.3%
Div Yield
6.78%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,000,000 -15,088,000 64,050,000 230,864,000 31,120,000 199,744,000 -9,145,000
Dec 2024 0 -12,781,000 -19,060,000 155,278,000 9,931,000 146,265,000 -8,412,000
Dec 2023 1,340,000 -15,769,000 5,525,000 220,551,000 57,658,000 163,821,000 -10,295,000
Dec 2022 2,703,000 -40,598,000 -36,561,000 161,642,000 10,486,000 151,812,000 -27,918,000

TTM Snapshot

Revenues TTM
$-3,324,000
NetIncome TTM
$174,870,000
OpCashFlow TTM
—
Assets (Latest)
$369,643,000
Forward EPS
$-0.08

Peers — same industry

TickerNameMarket CapLastDaily %
KRRO Korro Bio, Inc. $169.10M $12.32 —
ELDN Eledon Pharmaceuticals, Inc. $167.23M $1.98 —
IFRX InflaRx N.V. $169.47M $1.15 —
PYXS Pyxis Oncology, Inc. $172.24M $1.44 —
SLGL Sol-Gel Technologies Ltd. $172.97M $52.83 —

News headlines (Yahoo Finance, 1h cache)

Oramed: Q3 Earnings Snapshot
2026-11-12 22:36 · Yahoo
ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness
2026-08-28 09:30 · Yahoo
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
2026-06-17 12:55 · Yahoo
ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community
2026-06-18 12:21 · Yahoo
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors
2026-04-14 18:06 · Yahoo
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
2026-09-08 12:30 · Yahoo
ORMP: Strategically Acquiring Interests in Medtech & Technology Companies
2026-06-08 13:08 · Yahoo
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
2026-08-17 12:00 · Yahoo
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
2026-06-25 15:35 · Yahoo
June 2026 Penny Stocks To Watch For Potential Growth
2026-06-15 18:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.